MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

0.7450 -0.0327 (-4.20%)

Streaming Delayed Price Updated: 1:45 PM EDT, Aug 12, 2026 Add to My Watchlist

Price and Volume

Volume	16,527
Open	0.7725
Bid (Size)	0.7339 (200)
Ask (Size)	0.7449 (100)
Prev. Close	0.7777
Today's Range	0.7450 - 0.7851
52wk Range	0.6000 - 2.450
Shares Outstanding	41,876,087
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

August 06, 2026

From Mira Pharmaceuticals, Inc.

Via GlobeNewswire

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

July 30, 2026

Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate Development

From Mira Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	-50.0%	-50.0%
1 Month	-18.1%	-18.1%
3 Month	-27.0%	-27.0%
6 Month	-38.4%	-38.4%
1 Year	-47.5%	-47.5%

More News

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

July 10, 2026

From MIRA Pharmaceuticals

Via ACCESS Newswire

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

July 06, 2026

From MIRA Pharmaceuticals

Via ACCESS Newswire

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

June 25, 2026

From MIRA Pharmaceuticals

Via ACCESS Newswire

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

June 17, 2026

From MIRA Pharmaceuticals

Via ACCESS Newswire

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

June 04, 2026

Via ACCESS Newswire

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

May 27, 2026

Via ACCESS Newswire

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

May 14, 2026

Via ACCESS Newswire

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

May 13, 2026

Via ACCESS Newswire

Wondering what's happening in today's after-hours session? ↗

April 01, 2026

Via Chartmill

What's Going On With MIRA Pharma Stock Tuesday? ↗

March 24, 2026

Via Benzinga

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

March 23, 2026

Via ACCESS Newswire

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

March 04, 2026

Via ACCESS Newswire

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study

February 03, 2026

Via ACCESS Newswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 10, 2025

Via Benzinga

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

October 24, 2025

Via ACCESS Newswire

In today's session, these stocks are experiencing unusual volume. ↗

October 17, 2025

Via Chartmill

Mag 7 Undercard Stocks: PRSO, MIRA, WHWK, RDZN Surge on AI, Biotech, and Technology News – Full List Inside

October 17, 2025

Via AB Newswire

Which stocks are experiencing notable movement on Thursday? ↗

October 16, 2025

Via Chartmill

MIRA Pharmaceuticals Stock Surges Following Positive Preclinical Data ↗

October 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 16, 2025

Via Benzinga

Dow Dips Over 100 Points; US Crude Oil Inventories Surge ↗

October 16, 2025

Via Benzinga

Top movers analysis in the middle of the day on 2025-10-16: top gainers and losers in today's session. ↗

October 16, 2025

Via Chartmill

Thursday's session: gap up and gap down stocks ↗

October 16, 2025

Via Chartmill

Frequently Asked Questions

Is MIRA Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, MIRA Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does MIRA Pharmaceuticals, Inc. - Common Stock trade on?

MIRA Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock is MIRA on the Nasdaq Stock Market

What is the current price of MIRA Pharmaceuticals, Inc. - Common Stock?

The current price of MIRA Pharmaceuticals, Inc. - Common Stock is 0.7450

When was MIRA Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of MIRA Pharmaceuticals, Inc. - Common Stock was at 08/12/26 01:45 PM ET

What is the market capitalization of MIRA Pharmaceuticals, Inc. - Common Stock?

The market capitalization of MIRA Pharmaceuticals, Inc. - Common Stock is 31.20M

How many shares of MIRA Pharmaceuticals, Inc. - Common Stock are outstanding?

MIRA Pharmaceuticals, Inc. - Common Stock has 31M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.